Amilorid

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Achtung

• Gefahrenhinweise

  H300：Lebensgefahr bei Verschlucken.

  H315：Verursacht Hautreizungen.

  H319：Verursacht schwere Augenreizung.

  H412：Schädlich für Wasserorganismen, mit langfristiger Wirkung.

• Sicherheit

  P264：Nach Gebrauch gründlich waschen.

  P264：Nach Gebrauch gründlich waschen.

  P270：Bei Gebrauch nicht essen, trinken oder rauchen.

  P273：Freisetzung in die Umwelt vermeiden.

  P280：Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

  P301+P310：BEI VERSCHLUCKEN: Sofort GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

  P302+P352：BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

  P321：Besondere Behandlung

  P330：Mund ausspülen.

  P332+P313：Bei Hautreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

  P362：Kontaminierte Kleidung ausziehen und vor erneutem Tragen waschen.

  P405：Unter Verschluss aufbewahren.

  P501：Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

AMILORIDE Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Amyloride is also a potassium sparing diuretic that exhibits moderate activity. It is not an antagonist of aldosterone. It inhibits reabsorption of sodium ions and reduces excretion of potassium ions.

• Originator

  Midamor,Merck,UK,1971

• Verwenden

  Diuretic.

• Verwenden

  Amyloride is rarely used individually—as a rule it is used in combination with thiazides or loop diuretics. It is mainly used in combination with thiazide diuretics for cardiac insufficiency and hypertension, especially in cases where it is necessary to prevent hypokalemia.

• Verwenden

  Amiloride is an epithelial sodium channel blocker.

• Definition

  ChEBI: A monocarboxylic acid amide that is N-carbamimidoylpyrazine-2-carboxamide substituted by amino groups at positions 3 and 5 and a chloro group at position 6.

• Manufacturing Process

  Step A: Preparation of methyl 3-amino-5,6-dichloropyrazinoare: Methyl 3- aminopyrazinoate (765 g, 5 mols) is suspended in 5 liters of dry benzene. While stirring under anhydrous conditions sulfuryl chloride (1.99 liters, 3.318 g, 24.58 mols) is added over a period of 30 minutes and stirring is continued for 1 hour. During this period, the temperature rises to about 50°C and then begins to drop. The mixture is heated cautiously to reflux (60°C), refluxed for 5 hours and then stirred overnight at room temperature. The excess sulfuryl chloride is distilled off at atmospheric pressure (distillation is stopped when vapor temperature reaches 78%). The dark red mixture is chilled to 6°C. The crystals are filtered off, washed by displacement with two 100 ml portions of cold (8°C) benzene, then washed with 300 ml petroleum ether and dried in vacuum at room temperature, yielding 888 g (80%) of methyl 3-amino-5,6- dichloropyrazinoate in the form of red crystals, MP 228-230°C. The crude product is dissolved in 56 liters of boiling acetonitrile and passed through a heated (70-80°C) column of decolorizing charcoal (444 g). The column is washed with 25 liters of hot acetonitrile, the combined eluate concentrated in vacuum to about 6 liters and chilled to 5°C. The crystals that form are filtered, washed three times with cold acetonitrile, and air dried to constant weight, yielding 724 g (82% recovery, 66% overall) of methyl 3-amino-5,6- dichloropyrazinoate in the form of yellow crystals, MP 230-234°C. After additional recrystallizations from acetonitrile the product melts at 233-234°C.
  Step B: Preparation of methyl-3,5diamino-6-chloropyrazinoete: In a 2-liter, 3-necked flask fitted with a a mechanical stirrer, thermometer and gas inlet tube is placed dry dimethyl sulfoxide (1 liter). Methyl 3-amino-5,6- dichloropyrazinoate (100 g, 0.45 mol) is added and the mixture stirred and heated at 65°C on a steam bath until solution is effected. A stream of dry ammonia gas is admitted to the solution with continuous stirring, over a period of 45 minutes while the temperature is maintained at 65-70°C. The solution is cooled to about 10°C with continuous stirring and ammonia gas is admitted for an additional 1 1/4 hours. The yellow reaction mixture is poured, with stirring, into cold water (2 liters) and the light yellow solid that separates is removed by filtration, thoroughly washed with water, and dried in a vacuum desiccator to give 82.5 g (91%) of methyl 3,5-diamino-6-chloropyrazinoate, MP 210-212°C. Recrystallization from acetonitrile gives material melting at 212-213°C.
  Step C: Preparation of the base: A 300 ml one-necked, round-bottomed flask, equipped with a water-cooled condenser, calcium chloride tube and magnetic stirrer is charged with anhydrous methanol (150 ml) and sodium metal (5.75 g, 0.25 g atom). When the reaction is complete, the solution is treated with dry guanidine hydrochloride (26.3 g, 0.275 mol) and stirred for 10 minutes. The sodium chloride that forms is removed by filtration. The solution is concentrated in vacuum to a volume of 30 ml and the residue treated with the product of Step B, heated one minute on a steam bath and kept at 25°C for 1 hour. The product is filtered, washed well with water, dissolved in dilute hydrochloric acid and the free base precipitated by addition of sodium hydroxide to give the amiloride product base, a solid which melts at 240.5- 241.5°C.
  To produce the hydrochloride, the base is suspended in water (70 ml) and treated with sufficient 6 N hydrochloric acid to dissolve the free base. The solution is filtered and treated with concentrated hydrochloric acid (5 ml). The hydrochloride salt (22 g, 97%) separates and is recrystallized from water (50 ml) containing concentrated hydrochloric acid (3 ml).

• Trademarks

  Midamor (Merck).

• Therapeutic Function

  Diuretic

• Clinical Use

  Amiloride, another potassium-sparing diuretic, is an aminopyrazine structurally related to triamterene as an open-chain analogue. Similar to triamterene, it interferes with the process of cationic exchange in the distal convoluted tubule by blocking luminal sodium channels. It blocks the reabsorption of sodium ion and the secretion of potassium ion. It has no effect on the action of aldosterone. Oral amiloride is approximately 50% absorbed, with a duration of action of 10 to 12 hours, which is slightly longer than that for triamterene. Although triamterene is extensively metabolized, approximately 50% of amiloride is excreted unchanged. Renal impairment can increase its elimination half-life. Like triamterene, amiloride combined with a thiazide or loop diuretic is used to treat edema or hypertension.

• Synthese

  Amyloride, N-amidino-3,5-diamino-6-chloropirazincarboxamide (21.5.18), is synthesized from 5,6-diaminouracil, which upon reaction with glyoxal transforms into a pyrazineopyrimidine derivative (21.5.14), which decomposes upon further reaction with a strong alkaline, forming 3-aminopirazin-2-carboxylic acid (21.5.15). This is esterified into the corresponding methyl ester (21.5.16), and subsequently treated with sulfonyl chloride and ammonia, which gives the methyl ester of 3,5-diamino-6-chloropirazin-2-carboxylic acid (21.5.17). Reacting this with guanidine gives amyloride (21.5.18).

  

• Enzyminhibitor

  This potassium-sparing diuretic (FW = 229.63 g/mol; CAS 2016-88-8; Absorbance at 10 mg/mL (water) = 642 at 212 nm, 555 at 285 nm, and 617 at 362 nm; pKa = 8.7; Soluble in hot water (50 mg/mL), yielding a clear, yellow-green solution), also known as MK 870, Midamor?, and 3,5- diamino-6-chloro-N- (diaminomethylene) pyrazine-2-carboxamide, is an epithelial sodium channel (or ENaC) blocker used to manage hypertension and congestive heart failure (1-4). Two classes of Na+ transporters are sensitive to this drug: (a) the conductive Na+ entry pathway found in electrically high resistance epithelia and (b) a Na+-H+ electroneutral exchange system found in certain leaky epithelia, such as the renal proximal tubule. Amiloride exhibits a Ki value of <1 μM for the kidney transporter and approximately 1 mM in the colon. Midamor is a potassium- conserving (antikaliuretic) drug that possesses weak (compared with thiazide diuretics) natriuretic, diuretic, and antihypertensive activity. Like other potassium-conserving agents, amiloride may cause hyperkalemia (i.e., serum K+ levels >5.5 mEq/L), which, if uncorrected, can be fatal. Amiloride-induced hyperkalemia occurs in ~10% of patients, when used without a kaliuretic diuretic. This complication is more frequent in patients showing evidence of renal impairment and diabetes mellitus. When used along with a thiazide diuretic in patients without these complications, the risk of Amiloride-induced hyperkalemia drops to 1-2%. Amiloride is not metabolized by the liver and is instead excreted unchanged by the kidney. Amiloride displaces both adenosine A1 receptor agonist and antagonist binding with a Ki value in the low micromolar range, when assayed in calf brain membranes. Inhibition is counteracted by NaCl and protons. Amiloride (IC50 = 0.25 mM) and 5- (N-ethyl-N-isopropyl) amiloride (IC50 = 0.11 mM) also inhibit coxsackievirus B3 RNA polymerase in a single- nucleotide incorporation assay, although the argument that amiloride competes with incoming nucleoside triphosphates is unconvincing. A high- fidelity RNA dependent CVB3 RNA polymerase (RdRp) variant is amiloride-resistant.

AMILORIDE Upstream-Materialien And Downstream Produkte

Amilorid Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(44)Suppliers

2609-46-3, AMILORIDE Verwandte Suche: